MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Cost of Revenue 2011-2026 | QTNT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 M | 17.8 M | 17.2 M | 10.5 M | 10.8 M | 9.66 M | 9.76 M | 8.41 M | 7.17 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 M | 7.17 M | 12.4 M |
Quarterly Cost of Revenue Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.9 M | 31.1 M | 27.2 M | - | 7.93 M | 17.6 M | 9.65 M | 5.29 M | 4.97 M | 4.97 M | 4.5 M | 5.41 M | 4.53 M | 4.53 M | 3.97 M | 4.56 M | 4.19 M | 4.19 M | 4.55 M | - | 2.32 M | 2.79 M | 2.83 M | - | 2.6 M | 8.45 M | 5.85 M | - | 2.22 M | 7.1 M | 4.88 M | - | 2.2 M | 7.36 M | 5.16 M | - | 1.94 M | 6.27 M | 4.33 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.1 M | 1.94 M | 6.65 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
2.91 B | $ 111.16 | -2.04 % | $ 33.8 B |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
518 M | $ 13.26 | -2.07 % | $ 3.77 B | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.25 | -12.16 % | $ 175 M |  China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.03 | -2.71 % | $ 667 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 196.67 | -0.75 % | $ 21.8 B | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
9.69 M | $ 8.45 | - | $ 33.7 M |  Israel |
 |
DexCom
DXCM
|
1.86 B | $ 62.38 | -5.61 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.72 | -4.06 % | $ 475 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
349 M | $ 84.78 | -3.77 % | $ 10.6 B | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 102.7 | -0.37 % | $ 8.47 B |  Irlanda |
 |
Illumina
ILMN
|
1.51 B | $ 118.42 | -4.81 % | $ 18.8 B | USA |
 |
Interpace Biosciences
IDXG
|
17 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 165.13 | -2.52 % | $ 28.4 B | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 74.66 | -2.23 % | $ 5.04 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.43 | -4.22 % | $ 410 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.7 | 2.4 % | $ 2.52 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 7.55 | -2.77 % | $ 967 M | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.85 | -3.33 % | $ 1.92 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |